Abdera Therapeutics
Emma Cummins has extensive work experience in the pharmaceutical and biomedical research industry. Emma is currently employed at Abdera Therapeutics as a Director, previously having held the position of Associate Director. Prior to that, they worked at adMare BioInnovations as an Associate Director for seven years. Emma also worked at GSK as an Investigator, at Novartis Institutes for BioMedical Research as a Scientist, and at Pfizer as a Senior Scientist. Emma started their career as a Scientist at the Royal College of Surgeons in Ireland and Trinity College Dublin. Emma also worked as a Research Associate at Wyeth and as a Research Assistant at Boston University School of Medicine.
Emma Cummins attended Trinity College Dublin from 1994 to 1998 where they obtained a Bachelor of Arts (Hons) degree in Microbiology. Emma then pursued further education at the same institution from 1998 to 1999, earning a Master of Science degree in Molecular Medicine.
This person is not in any offices
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.